| Literature DB >> 34262178 |
Cameron S McAlpine1,2,3, Joseph Park4, Ana Griciuc4, Eunhee Kim4, Se Hoon Choi4, Yoshiko Iwamoto1, Máté G Kiss1, Kathleen A Christie5, Claudio Vinegoni1, Wolfram C Poller1,2, John E Mindur1, Christopher T Chan1, Shun He1, Henrike Janssen1, Lai Ping Wong6,7, Jeffrey Downey1, Sumnima Singh1, Atsushi Anzai1, Florian Kahles1, Mehdi Jorfi4, Paolo Fumene Feruglio8, Ruslan I Sadreyev6,9, Ralph Weissleder1, Benjamin P Kleinstiver5, Matthias Nahrendorf1, Rudolph E Tanzi10, Filip K Swirski11,12.
Abstract
Communication within the glial cell ecosystem is essential for neuronal and brain health1-3. The influence of glial cells on the accumulation and clearance of β-amyloid (Aβ) and neurofibrillary tau in the brains of individuals with Alzheimer's disease (AD) is poorly understood, despite growing awareness that these are therapeutically important interactions4,5. Here we show, in humans and mice, that astrocyte-sourced interleukin-3 (IL-3) programs microglia to ameliorate the pathology of AD. Upon recognition of Aβ deposits, microglia increase their expression of IL-3Rα-the specific receptor for IL-3 (also known as CD123)-making them responsive to IL-3. Astrocytes constitutively produce IL-3, which elicits transcriptional, morphological, and functional programming of microglia to endow them with an acute immune response program, enhanced motility, and the capacity to cluster and clear aggregates of Aβ and tau. These changes restrict AD pathology and cognitive decline. Our findings identify IL-3 as a key mediator of astrocyte-microglia cross-talk and a node for therapeutic intervention in AD.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34262178 PMCID: PMC8934148 DOI: 10.1038/s41586-021-03734-6
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962